2. Search Result
Search Result
Results for "

drug-resistant Mycobacterium tuberculosis

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

1

Peptides

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W040128
    Kanamycins sulfate

    		Antibiotic Autophagy JNK Bcl-2 Family Infection
    Kanamycins sulfate is a blood-brain barrier-permeable JNK1 and Bcl-2 modulator as well as an antibiotic, with broad-spectrum antibacterial, and biofilm-inhibiting activities, and it induces autophagy. Kanamycins sulfate promotes Bcl-2 phosphorylation to upregulate autophagy levels, triggering changes such as mitochondrial swelling and endoplasmic reticulum expansion. Consequently, it causes reversible neuronal damage in the dorsal cochlear nucleus without inducing significant neuronal apoptosis. In the presence of exogenous alanine or glucose, Kanamycins sulfate effectively kills drug-resistant bacteria, restores drug sensitivity of multidrug-resistant bacteria, and alleviates urinary tract and kidney infections in mice. Kanamycins sulfate can be applied to scientific research related to Mycobacterium tuberculosis, salmonellosis, brucellosis, shigellosis, urinary tract infections, and reversible neurotoxicity .
    Kanamycins sulfate
  • HY-125576
    Griselimycin

    		Bacterial Infection
    Griselimycin is a cyclic lipopeptide produced by Streptomyces. Griselimycin specifically binds to the sliding clamp of bacterial DNA polymerase and does not interact with human PCNA. Griselimycin exhibits potent antibacterial activity against Mycobacterium tuberculosis (including drug-resistant strains) and a variety of Gram-negative bacteria .
    Griselimycin
  • HY-12930
    SPR719
    4 Publications Verification

    VXc-486

    		 Topoisomerase Bacterial Infection
    SPR719 (VXc-486) is an orally active gyrase B inhibitor, with bactericidal activity. SPR719 potently inhibits multiple agent-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis, with MICs of 0.03 to 0.30 μg/ml and 0.08 to 5.48 μg/ml, respectively. SPR719 is promising for research of lung disease caused by non-tuberculous mycobacteria (NTM) .
    SPR719
  • HY-135748A
    Poly (I:C):Kanamycin (1:1) sodium
    Maximum Cited Publications
    56 Publications Verification

    		 RIG-I-like receptor (RLR) Toll-like Receptor (TLR) Apoptosis Infection Cancer
    Poly (I:C):Kanamycin (1:1) sodium is an isometric complex of Poly (I:C) (HY-135748) and Kanamycin (HY-16566). Poly(I:C) sodium, a synthetic analog of double-stranded RNA, is a TLR3 and retinoic acid-inducible gene I receptor (RIG-I and b>MDA5) agonist. Poly(I:C) sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses and induce apoptosis in cancer cells . Kanamycin is an orally active antibacterial agent (Gram-negative/positive bacteria) that inhibits translocation and causes miscoding by binding to the 70S ribosomal subunit. Kanamycin shows good inhibitory activity against Mycobacterium tuberculosis (susceptible and drug-resistant) and Klebsiella pneumoniae, and can be used in the research of tuberculosis and pneumonia .
    Poly (I:C):Kanamycin (1:1) sodium
  • HY-113619
    ABT-255 free base

    		Bacterial Infection
    ABT-255 free base is an orally active anti-bacterial agent. ABT-255 free base exhibits potent in vitro potency (MIC = 0.016-0.031 μg/mL) against drug-susceptible and Rifampin (HY-B0272)- or Ethambutol (HY-B0535)-resistant Mycobacterium tuberculosis. ABT-255 free base shows efficacy against S. aureus, S. pneumoniae and E. coli and reduces viable counts of drug-resistant Mycobacterium tuberculosis in CF-1 mice. ABT-255 free base can be used for the study of pulmonary tuberculosis .
    ABT-255 free base
  • HY-76293
    I2906
    1 Publications Verification

    		 Bacterial Infection
    I2906 is an orally active isocitrate lyase (ICL) inhibitor with a Mycobacterium tuberculosis IC50 of 134.3 μg/mL. I2906 inhibits the growth of Mycobacterium tuberculosis. I2906 can be used for the research of tuberculosis .
    I2906
  • HY-114604
    Propioxatin B

    		Bacterial Others
    Propioxatin B is a tricyclic sesquiterpenoid compound isolated from the root of vetiver grass. It has anti-tuberculosis activity and inhibitory effects on a variety of drug-resistant mutants of Mycobacterium tuberculosis. In computer simulation docking studies, it showed binding affinity with bacterial DNA gyrase and has a certain safety in vivo.
    Propioxatin B
  • HY-162508
    KSK-104

    		Bacterial Infection
    KSK-104 has potent antibacterial activity against Mycobacterium tuberculosis (MIC=0.78 μM). The role of KSK-104 is mainly involved in the synthesis and recovery pathways of pyridoxal 5'-phosphate (PLP), PLP-dependent enzymes and oxidative stress networks. KSK-104, as a candidate molecule for novel anti-tuberculosis drugs, can be used to develop research against drug-resistant mycobacterium tuberculosis .
    KSK-104
  • HY-149346
    Mtb-IN-2

    		Bacterial Infection
    Mtb-IN-2 (compound 10c) is an antimicrobial agent against Mycobacterium tuberculosis (Mtb), without cytotoxicity. Mtb-IN-2 significantly decreases colony-forming units (CFU) in spleen of murine tuberculosis models, and distinguishes both drug-sensitive and drug-resistant Mtb H37Rv strains. Mtb-IN-2 affects methionine metabolism but not folate pathway directly.
    Mtb-IN-2
  • HY-113619A
    ABT-255 hydrochloride

    		Bacterial Infection
    ABT-255 hydrochloride is an orally active anti-bacterial agent. ABT-255 hydrochloride exhibits potent in vitro potency (MIC = 0.016-0.031 μg/mL) against drug-susceptible and Rifampin (HY-B0272)- or Ethambutol (HY-B0535)-resistant Mycobacterium tuberculosis. ABT-255 hydrochloride shows efficacy against S. aureus, S. pneumoniae and E. coli and reduces viable counts of drug-resistant Mycobacterium tuberculosis in CF-1 mice. ABT-255 hydrochloride can be used for the study of pulmonary tuberculosis .
    ABT-255 hydrochloride
  • HY-183606
    Mycobacterium tuberculosis-IN-9

    		Bacterial Infection
    Mycobacterium tuberculosis-IN-9 is an orally active Mycobacterium tuberculosis BioA inhibitor with a Ki value of 0.2 nM. Mycobacterium tuberculosis-IN-9 targets the biotin biosynthesis pathway. Mycobacterium tuberculosis-IN-9 inhibits the growth of Mycobacterium tuberculosis in mouse models and is effective against both drug-sensitive and drug-resistant strains. Mycobacterium tuberculosis-IN-9 can be used for the research of tuberculosis .
    Mycobacterium tuberculosis-IN-9
  • HY-183323
    MmpL3-IN-6

    		Bacterial Infection
    MmpL3-IN-6 is a mycobacterial membrane protein large 3 (MmpL3) transporter inhibitor and is an antitubercular agent. MmpL3-IN-6 exerts bactericidal activity against replicating Mycobacterium tuberculosis.MmpL3-IN-6 retains activity against drug-resistant Mycobacterium tuberculosis.MmpL3-IN-6 can be used for the research of tuberculosis .
    MmpL3-IN-6
  • HY-W353258R
    Moxifloxacin hydrochloride monohydrate (Standard)

    BAY 12-8039 monohydrate (Standard)

    		 Reference Standards Antibiotic Topoisomerase Bacterial Infection
    Moxifloxacin hydrochloride (BAY 12-8039) monohydrate (Standard) is the analytical standard of Moxifloxacin hydrochloride monohydrate. This product is intended for research and analytical applications. Moxifloxacin hydrochloride monohydrate is a blood-brain barrier-permeable, orally active topoisomerase II/IV inhibitor and a fluoroquinolone antibiotic. Moxifloxacin hydrochloride monohydrate disrupts bacterial DNA replication, transcription, repair and chromosome segregation processes. Moxifloxacin hydrochloride monohydrate exhibits activity against Gram-positive bacteria, Gram-negative bacteria, anaerobes, atypical pathogens, drug-resistant respiratory pathogens, Mycobacterium tuberculosis, mycoplasmas and Ureaplasma urealyticum.
    Moxifloxacin hydrochloride monohydrate (Standard)
  • HY-170970
    Mtb-IN-10

    		Bacterial Infection
    Mtb-IN-10 (Compound P15) is a Rv1625c/Cya activator that regulates cAMP metabolism to influence the growth of Mycobacterium tuberculosis (Mtb). Mtb-IN-10 exhibits an EC50 of 1.96 µM in an Mtb-infected macrophage model and demonstrates 58.0% oral bioavailability in mice at a 20 mg/kg dose. It may regulate intracellular signaling and disrupt cholesterol metabolism in Mtb, thereby inhibiting bacterial proliferation. Mtb-IN-10 holds potential for tuberculosis (TB) research, particularly for combating multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) Mtb strains .
    Mtb-IN-10
  • HY-175016
    NADH-IN-3

    		Endogenous Metabolite Infection Metabolic Disease
    NADH-IN-3 (Compound C4-1) is a NADH inhibitor with a MIC of 4 μg/mL (13.042 μM) for type II NADH dehydrogenase of Mycobacterium tuberculosis (Mtb). NADH-IN-3 significantly interrupts ATP synthesis, shows potent inhibitory effects against mono (Rifampicin (HY-B0272) and Isoniazid (HY-B0329)) and multi drug-resistant (Mtb) strains and an anti-bactericidal activity against HepG2 cells with low cytotoxicity (SI: 16.52) .
    NADH-IN-3
  • HY-124195
    Antitubercular agent-57

    		Bacterial Infection
    Antitubercular agent-57 is a selective antimycobacterial agent with low in vitro toxicity against mammalian cell lines including hepatocyte cell lines. Antitubercular agent-57 exhibits activity against drug-sensitive, multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains, and shows no cross-resistance with first-line or second-line antitubercular agents. Antitubercular agent-57 has no activity against Gram-positive bacteria, Gram-negative bacteria and fungal strains. Antitubercular agent-57 can be used in the research of tuberculosis and multidrug-resistant tuberculosis .
    Antitubercular agent-57
  • HY-181866
    Antibacterial agent 328

    		Bacterial Infection
    Antibacterial agent 328 is a enoyl-ACP reductase (InhA) inhibitor and antimycobacterial agent. Antibacterial agent 328 blocks mycolic acid biosynthesis in Mycobacterium tuberculosis. Antibacterial agent 328 acts on both drug-resistant and drug-susceptible Mycobacterium tuberculosis strains. Antibacterial agent 328 exhibits favorable pharmacokinetic properties, drug-likeness, and a safety-related selectivity index. Antibacterial agent 328 can be used for research on tuberculosis .
    Antibacterial agent 328
  • HY-180790
    Antimycobacterial agent-15

    		Bacterial Infection
    Antimycobacterial agent-15 (Compound 55) is a highly selective anti-mycobacterial agent that has an MIC99 of 8 μM against Mycobacterium tuberculosis H37Rv. Antimycobacterial agent-15 exhibits significant efficacy against multidrug-resistant and extensively drug-resistant isolates. This agent can be used in the research of tuberculosis .
    Antimycobacterial agent-15
  • HY-180407
    UGM-IN-1

    		Bacterial Infection
    UGM-IN-1 (compound 107) is a selective competitive inhibitor of Mycobacterium tuberculosis UDP-Galp mutase (UGM), encoded by Rv3809c. UGM-IN-1 inhibits the conversion of UDP-galactopyranose (UDP-Galp) to UDP-galactofuranose (UDP-Galf), thereby blocking the synthesis of key components of the mycobacterial cell wall, including mycolic acid-arabinogalactan (mAG) and liparabinomannan (LAM), leading to anti-mycobacterial activity against Mycobacterium tuberculosis. UGM-IN-1 is useful for research on tuberculosis, including drug-resistant tuberculosis .
    UGM-IN-1
  • HY-181286
    ETX1975-3

    		Cytochrome P450 Infection
    ETX1975-3 is an orally active inhibitor and bactericide targeting the bd cytochrome oxidase of Mycobacterium tuberculosis. ETX1975-3 disrupts electron transfer between the b-heme centers of the target enzyme, and in combination with Q203 (HY-101040), exerts bactericidal activity against both replicating and non-replicating Mycobacterium tuberculosis, and reduces bacterial loads in acute mouse models. ETX1975-3 retains activity against clinical isolates of multidrug-resistant/extensively drug-resistant Mycobacterium tuberculosis and non-tuberculous mycobacteria, while possessing favorable preclinical ADMET properties. ETX1975-3 can be used in studies related to tuberculosis and non-tuberculous mycobacterial infections .
    ETX1975-3
  • HY-181008
    Antitubercular agent-56

    		Bacterial Infection Inflammation/Immunology
    Antitubercular agent-56, a Questiomycin A (HY-N8439) derivative, is a potent and orally active antitubercular agent. Antitubercular agent-56 disrupts mycobacterial envelope integrity by inhibiting FabD (Kd = 9.39 μM; IC50 = 49.60 μM). Antitubercular agent-56 exhibits good intracellular antimycobacterial activity against Mycobacterium tuberculosis (MTB) and drug-resistant MTB both in vitro and in vivo. Antitubercular agent-56 can be used for research on tuberculosis (TB) .
    Antitubercular agent-56
  • HY-179649
    sALT629

    		Bacterial Infection
    sALT629 is an orally active antitubercular agent with potent intramacrophage activity (EC50 = 1.5 μM). sALT629 shows broad-spectrum anti-Mycobacterium tuberculosis (Mtb) activities across four carbon sources, equipotent efficacy against drug-resistant Mtb, and activity against both slow-replicating and nonreplicating Mtb. sALT629 exhibits synergistic activity when combined with oxazolidinone drugs, such as Linezolid (HY-10394) and Sutezolid (HY-10392). sALT629 can be used for the research of tuberculosis .
    sALT629
  • HY-183542
    DprE1-IN-15

    		Bacterial Infection
    DprE1-IN-15 is a covalent Mycobacterium tuberculosis essential cell wall enzyme DprE1 inhibitor with an IC50 of 0.073 μM. DprE1-IN-15 forms an irreversible covalent adduct with its target enzyme. DprE1-IN-15 shows inhibitory effects against multiple Mycobacterium tuberculosis .
    DprE1-IN-15
  • HY-181771
    IDD-AN-A1

    		Bacterial Infection
    IDD-AN-A1 is a potent Mycobacterium tuberculosis (Mtb) isocitrate lyase (ICL) inhibitor with an IC50 of 7 μg/mL. IDD-AN-A1 shows additive and synergistic activity with anti-tuberculosis agents. , respectively.IDD-AN-A1 exhibits potent anti-tuberculosis activity. IDD-AN-A1 can be used for the research of tuberculosis .
    IDD-AN-A1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: